Please use this identifier to cite or link to this item:
|Title:||Delaying acute graft-versus-host disease in mouse bone marrow transplantation by treating donor cells with antibodies directed at L-selectin and α4-integrin prior to infusion|
|Citation:||Li, B., New, J.Y., Tay, Y.K., Goh, E., Yap, E.H., Chan, S.H., Hu, H.Z. (2004-05). Delaying acute graft-versus-host disease in mouse bone marrow transplantation by treating donor cells with antibodies directed at L-selectin and α4-integrin prior to infusion. Scandinavian Journal of Immunology 59 (5) : 464-468. ScholarBank@NUS Repository. https://doi.org/10.1111/j.0300-9475.2004.01414.x|
|Abstract:||Acute graft-versus-host disease (GVHD) is still a major hurdle for successful bone marrow transplantation (BMT). Although many immunosuppressive drugs are available, none of them alone or in combination are able to completely abolish acute GVHD. The lifelong immunosuppression profoundly reduces the quality of life of BMT recipients. Therefore, new therapeutic approaches are needed. We previously reported that, in an acute GVHD model using SCID mice as recipient, incubating donor spleen cells with antibodies directed at CD49d and CD62L could significantly delay the occurrence of acute GVHD. To test the potential usefulness of this treatment in BMT, we examined this therapeutic protocol in a mouse BMT model. The present mouse BMT study confirmed our previous results that incubation of donor cells with antibodies directed at CD49d and CD62L prior to infusion into the recipient can effectively delay acute GVHD, allowing the recipients to recover from the side effects of total body irradiation. This one-time treatment is easy and simple and may be modified for clinical usage.|
|Source Title:||Scandinavian Journal of Immunology|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jun 17, 2018
WEB OF SCIENCETM
checked on Jun 5, 2018
checked on May 10, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.